News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cobra Biologics Ltd. Granted Approval For Research Tax Credit


4/1/2014 9:11:56 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

1 April 2014: Cobra Biologics is pleased to announce that the French Ministry of Higher Education and Research (MESR) has recognised the contract manufacturer as an approved service provider for its antibody and recombinant protein services for the period 2013 to 2015. French companies which outsource their research and development (R&D) programmes to Cobra’s centre of excellence for mammalian antibody and recombinant protein production will benefit from the research tax credit (Le Crédit d’Impôt Recherche).

The tax credit scheme from the MESR serves as a powerful incentive for research partnerships; encouraging research and development efforts, enhancing the France’s attractiveness for investment, and supporting the development of organisations within the country regardless of their size or industry.

All French companies incurring research expenses are eligible to receive this tax credit which covers 30% of all R&D expenses up to €100 million, and 5% above this threshold.

Peter Coleman, CEO Cobra Biologics, commented: “CIR is a real benefit to our French customers as it encourages them to invest in innovative drugs that are ultimately the driving force for the medicines of tomorrow.”

For more information about Cobra Biologics, please contact Peter Coleman, CEO, on +44 (0)1782 714181 or email peter.coleman@cobrabio.com

For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0)207 861 3019 or email: t.jervis@defacto.com.

About Cobra Biologics

Cobra Biologics is a leading international contract manufacturing organisation (CMO) of biologics and pharmaceuticals for clinical and commercial supply. Cobra has three GMP approved facilities, each with expertise tailored to serving our customers across the world. We offer a broad range of integrated and stand-alone contract services, stretching from cell line and process development through to fill and finish for the supply of products for clinical trials and the commercial market. We take pride in manufacturing excellence and being a trusted provider, delivering what we promise and helping our customers to develop medicines for the benefit of patients. Cobra supplies manufacturing solutions to the pharmaceutical industry covering antibodies, recombinant proteins, viruses, phage, DNA, whole cell vaccines and therapeutics as well as biologics and small molecule API lyophilisation and fill finish.

For more information please visit: www.cobrabio.com

For media enquiries, please contact Tristan Jervis on +44 (0) 207 203 6740 or e-mail: t.jervis@defacto.com.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES